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| INTRODUCTION
For more than 60 years, warfarin was the only standard oral anticoagulation agent available for use in the United States. As is well known, the use of warfarin requires close monitoring to ensure efficacy and safety, as well as avoidance of several drug-drug and drug-food in- (Tables 2 and 3) . 3, 4 Additionally, the new oral anticoagulants have few known drug-drug and drug-food interactions as compared to warfarin.
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While the acquisition cost of branded agents may initially be greater, a study utilizing a Markov model to assess the incremental costeffectiveness and quality-adjusted life years of patients with nonvalvular atrial fibrillation found that edoxaban appears to be economically beneficial when compared with dose-adjusted warfarin. 2 Analyses for each of the DOACs found similar results. 6 Despite these proposed clinical and economic benefits, there are insufficient data regarding the use of DOACs in selected patient populations. Dosing and treatment considerations of these agents have been reviewed previously. [7] [8] [9] The purpose of this article was to describe the novel pharmacology and mechanisms of action of the new oral anticoagulants as they relate to their use among solid organ transplant recipients. This will include discussion of dosing in patients with impaired renal and hepatic function, considerations for drug-drug interactions with immunosuppressive medications, and management of patients at the time of unplanned surgery.
| NOVEL MECHANISMS AND PHARMACOKINETICS
Dabigatran is a synthetic inhibitor of thrombin (Factor IIa). Due to limited bioavailability, dabigatran is formulated as a prodrug, dabigatran etexilate, which is a substrate of the P-glycoprotein (P-gp) efflux transporter. Considered a double prodrug, dabigatran etexilate is first hydrolyzed by carboxyl esterases to two mono prodrugs and then subsequently hydrolyzed to its active form in human plasma. Upon hydrolysis in the liver and in plasma, the active component reversibly binds to the catalytic domain of the thrombin enzyme ( Figure 1 ).
Dabigatran therefore inhibits fibrin-bound thrombin, free circulating thrombin, and thrombin-induced platelet aggregation. 10 Further information regarding specific pharmacokinetics is summarized in Table 2 .
Rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors, but unlike heparin, they do not require antithrombin III cofactor to selectively block factor Xa. These agents can inhibit free and clot-bound factor Xa and prothrombinase activity. Rivaroxaban is metabolized via oxidative degradation catalyzed by cytochrome P450 3A4/5 and 2J2 enzymes and by hydrolysis. It is also a substrate for the P-glycoprotein efflux transporter. Apixaban is also metabolized via the cytochrome P450 isoenzymes, primarily 3A4 and 1A2, 2C8, 2C9, and 2J2. Edoxaban, on the other hand, is not highly bound to plasma proteins and undergoes minimal metabolism via hydrolysis, conjugation, or oxidation by CYP 450 enzymes.
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| RENAL IMPAIRMENT
Each of the DOACs undergoes some component of renal elimination (Table 2) . In regard to exposure, it is therefore important to consider 
| Dabigatran in renal impairment
Approximately 80% of dabigatran is excreted as unchanged in the urine, and overall drug exposure is thought to increase with age and worsening of renal function. and 30 mL/min were expected to have similar drug exposure to that found among healthy subjects. Without any clinical data, the dose of 75 mg twice daily was chosen based on a lower peak-trough ratio than any single daily regimen and similar posology for all patient subgroups which might reduce medication errors and avoid a negative impact on adherence. 16, 17 There has been recent concern in utilizing dabigatran even in pa- System National Pharmacy and Laboratory extracts found that even in those patients who converted from warfarin to dabigatran with moderate renal dysfunction had a bleeding risk nearly three times higher when compared to patients who remained on warfarin. 18 These data from real-world clinical use highlight significant concern for use of dabigatran in renal impairment. 23 Another study which evaluated the pharmacokinetics of rivaroxaban after a single dose of 15 mg administered before and after hemodialysis in subjects with end-stage renal disease (ESRD) and in control subjects found that the patients on hemodialysis experienced a 56% increase in AUC and 35% decrease in overall drug clearance, similar to that described in patients with moderate or severe renal insufficiency. 24 Rivaroxaban has not been studied for any indication in patients with renal impairment, and while the aforementioned increases in AUC values are modest, the risk of active drug accumulation which may result in bleeding cannot be extrapolated from these small pharmacokinetic studies and therefore for the present time should be avoided.
| Rivaroxaban in renal impairment
An analysis of prescriptions for DOACs in patients with ESRD on hemodialysis found increasing use of dabigatran and rivaroxaban.
Based on prescription data from 2010 to 2014, the use of DOACs in this patient population resulted in a higher risk of hospitalization or death from bleeding for dabigatran (rate ratio, 
| Apixaban in renal impairment
Only 27% of the dose of apixaban is excreted renally. In the "Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial
Fibrillation" (ARISTOTLE) study, patients with NVAF were excluded if they had a serum creatinine >2.5 mg/dL or CL CR <25 mL/min. Dose adjustments were made for patients meeting two of the following criteria: age ≥80 years, body weight ≤60 kg, or a serum creatinine ≥1.5 mg/dL. 26 Other landmark studies for apixaban excluded patients with CL CR <25 mL/min or impaired renal function. [27] [28] [29] [30] There are no other clinical trials which evaluated apixaban in patients with severe renal impairment. A prespecified secondary analysis of ARISTOTLE found that the renal impairment group, defined as CL CR <50 mL/min, had higher rates of the primary outcome, all-cause mortality, and of major bleeding. Apixaban was more effective than warfarin in preventing stroke or systemic embolism, therefore resulting in reduced mortality irrespective of renal function, and was associated with fewer major bleeding events across all ranges of estimated glomerular filtration rate (eGFR). 
| Edoxaban in renal impairment
About 50% of edoxaban is recoverable as unchanged drug in the urine. Edoxaban is the only DOAC that is contraindicated in patients sis. An open-label study which evaluated the effect of a single dose of edoxaban in patients on hemodialysis found that total exposure of edoxaban was similar to that found in healthy patients with normal renal function. Notably, exposure for the pharmacologically active M-4 metabolite was much higher in this study as compared to previous studies.
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Normal renal function did not have the same effect for patients being treated for VTE in the Hokusai-VTE study, and therefore, this contraindication has not been found to be applicable for the use of edoxaban for the VTE indication. 39 A pharmacokinetic analysis in a pooled population, with data obtained from 13 separate phase I studies and from the Hokusai-VTE trial, found that edoxaban dose adjusted to renal function resulted in reduced exposure compared with the standard-dose group; this dose reduction, however, did not lead to any clinical differences in the subgroup analyses. 
| HEPATIC IMPAIRMENT
Liver dysfunction plays an important role in the pharmacokinetics and pharmacodynamics effects of a drug. Patients with significant liver disease were excluded from phase III registration trials for the DOACs. Currently, none of the DOACs are contraindicated in hepatic impairment, although there are recommendations to avoid certain agents depending on the severity of the patient's liver dysfunction. 15, 22, 35, 41 It is well known that drug absorption can be significantly affected in hepatic impairment; this is specifically found with compounds that undergo pivotal metabolic changes during the first-pass effect.
Porto-systemic shunting can reduce the effect of drug-metabolizing enzymes by bypassing this presystemic processing, particularly in cirrhotic patients. None of the DOACs have a high hepatic extraction ratio; therefore, differences in absorption in patients with hepatic impairment are generally not of major concern. It is important to note, however, that one of the DOACs, dabigatran, is a prodrug and thus may be subject to a reduction in the active form. 9 In a single-dose study, 150 mg of dabigatran was administered to both healthy controls and to patients with chronic Child-Pugh class B liver disease.
Conversion of the dabigatran intermediate to active dabigatran was
slower in patients with hepatic impairment, but there were no differences in total drug exposure. 42 The authors postulate that a portosystemic shunting effect may have been responsible for the slower conversion, although the clinical effect of this delay is unknown. In transplant patients with known hepatic congestion prior to transplantation, porto-systemic shunting should be considered when using dabigatran.
Drug distribution in patients with hepatic impairment is likely to be altered due to a reduction in plasma proteins. An enhanced pharmacodynamic response may be seen with drugs that have high affinity for plasma proteins. Dabigatran and edoxaban are not highly protein bound and so their distribution should not be greatly affected by changes in plasma proteins. Rivaroxaban and apixaban, on the other hand, are 92%-95% and 87% protein bound in plasma, respectively.
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In a study involving otherwise healthy volunteers who received a single dose of 10 mg of rivaroxaban, patients with Child-Pugh class B hepatic impairment had a lower serum albumin at baseline, and this correlated with presence of a higher fraction of unbound rivaroxaban in the serum. This resulted in a prolonged prothrombin time (PT) in the group with hepatic impairment.
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Liver disease is most often associated with metabolic deficiencies, and the metabolism of the DOACs has considerable variability among the various agents. Both rivaroxaban and apixaban undergo metabolic processing through the CYP 450 enzyme system. For volunteers receiving a single dose of 10 mg of rivaroxaban, patients with Child-Pugh class B hepatic impairment experienced reduced total body clearance of the drug and a 2.27-fold increase in total exposure secondary to reduced elimination and increased maximum concentration (C max ). 43 The authors postulated that this effect may have resulted from a decrease in hepatic CYP 450 enzyme activity.
Hepatic impairment can also impact agents that depend on hepatic excretion. DOACs with appreciable biliary excretion include apixaban and edoxaban (Table 2) . 9 A single-dose study in patients with mild or moderate hepatic impairment who received 15 mg of edoxaban did not have any increase in exposure or decrease in excretion of edoxaban. 
| Recommendations for hepatic impairment
As the quality of evidence is low in the studies listed above, it is difficult to make any conclusive recommendations about the use 
| DRUG INTERACTIONS
As discussed previously, the metabolism of the DOACs has considerable variability among the various agents and is dependent on the CYP 450 enzyme system and P-gp efflux pump (Table 2) NVAF and impaired renal function when simultaneously administering concomitant P-gp inhibitors; it also recommends avoidance of dabigatran for treatment of VTE in the same patient population (see Table 1 ). 15 Although little information is available about the effect of other P-pg inhibitors on dabigatran exposure, caution in its use is warranted in transplant recipients who are concomitantly treated with CNIs. Calcineurin inhibitors are known substrates of both CYP 450 3A4 and P-gp, as well as inhibitors of P-gp. Cyclosporine also inhibits the CYP 450 3A4 enzyme.
| Dabigatran drug interactions
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It should be noted that although clinical recommendations based on underpowered analysis cannot be made, in a single-center experience in nine heart transplant recipients immunosuppressed with CNIs and treated with dabigatran for atrial fibrillation, VTE, or atrial thrombus, changes in CNI dose were required. 53 When compared to anti-Xa inhibitors, patients prescribed dabigatran were more likely to require a decrease in tacrolimus dose during therapy (P=.036) and numerically had more major bleeding events (P=.065)
when dabigatran was utilized with CNIs. However, appropriately powered studies are required to be able to make data-based clinical recommendations.
| Rivaroxaban drug interactions
The prescribing information for rivaroxaban recommends avoiding administration of this drug together with dual-inhibitors of P-gp and CYP 450 3A4 as this may increase the exposure of rivaroxaban. While the package insert calls for avoidance of rivaroxaban with dual P-gp and CYP3A4 inhibitors, it is important to consider all other drugs used by the transplant recipient. As transplant recipients are frequently treated with many agents, other than CNIs, that can impact CYP3A4 and P-gp, this interaction is easily overlooked. Drug interaction software provided by Lexicomp ® rates the interaction of rivaroxaban and calcineurin inhibitors with a risk rating of B, no action needed, contingent upon a number of notable dependencies including additional drugs/groups (CYP3A4 inhibitors), international labeling considerations, and renal function. 56 Micromedex Solutions ® does not list any drug interaction between CNIs and rivaroxaban, and Clinical Pharmacology ® rates only rivaroxaban and cyclosporine as a minor drug-drug interaction (Table 3) . 57, 58 As the number of transplant patients requiring anticoagulation increases, the severity of these variations in the reported interaction may frequently influence clinical decisions and most recent studies and evaluations should be consulted for accurate reference frequently.
To our knowledge, there has only been one study which assessed [±14.4] ng/mL). 59 It is unknown whether CNIs' impact on rivaroxaban exposure would be more significant if target concentrations were considerably higher, as they usually are in the first 6-12 months following transplantation.
These findings parallel a previous study in renal transplant recipients which demonstrated that cyclosporine led to a substantial inhibition of P-gp activity as compared to tacrolimus or sirolimus. The authors suggest that the average 40-fold higher dose of cyclosporine is responsible for achieving inhibitory concentrations on both intestinal and hepatic P-gp. 60 Therefore, the rivaroxaban-cyclosporine interaction may be clinically more relevant than that of the rivaroxabantacrolimus drug interaction.
| Apixaban drug interactions
Similar to rivaroxaban, apixaban is metabolized by both the CYP 450 enzyme system as well as P-gp. While phase III studies for apixaban excluded patients taking concomitant inhibitors of CYP 3A4/P-gp, the prescribing information recommends a 50% dose decrease when coadministered with drugs that are strong dual-inhibitors including ketoconazole, itraconazole, ritonavir, or clarithromycin. 41 In a study with healthy volunteers, coadministration of apixaban with ketoconazole was associated with a 99% increase in AUC. 61 For patients already prescribed a dose of 2.5 mg twice daily, coadministration should be avoided.
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| Edoxaban drug interactions
Although edoxaban is eliminated via several pathways, P-gp is the primary route of its elimination. 62 In ENGAGE AF-TIMI 48, patients treated concomitantly with strong P-gp inhibitors including verapamil, quinidine, or dronedarone required a 50% dose reduction in edoxaban. 63 This recommendation was based on a pharmacokinetic modeling study that supported reduction in the dose by half in patients with moderate renal insufficiency or in those treated with strong P-gp inhibitors including ketoconazole, erythromycin, azithromycin, quinidine, verapamil, and dronedarone. 64 This strategy aimed to provide patients with similar edoxaban exposure compared to those patients who did not receive P-gp inhibitor cotreatment and had normal renal function. This approach was later validated
by a large population-based pharmacokinetic study including patients from all of the phase I atrial fibrillation studies. 65 However, subgroup analysis of the ENGAGE-TIMI 48 trial found that a greater number of strokes or systemic emboli occurred in patients on dosereduced edoxaban presumably due to drug interactions, HR 2.17
(95% CI 0.66-7.06), although these findings were not statistically significant. 66 This may be partially explained by population pharmacokinetic analyses of edoxaban patients enrolled in the ENGAGE AF-TIMI 48 study which found that the 50% dose reduction in patients with low weight (≤60 kg), moderate renal impairment (CL CR ≤50 mL/min), or concomitant P-gp inhibitors led to 30% lower exposure to the drug than that found in patients without a dose reduction. 67 The prescribing information does not list a dose adjustment for edoxaban when used in NVAF with concomitant P-gp inhibitors; however, a maximum edoxaban dose of 30 mg daily should be used for VTE treatment when utilized with a concomitant P-gp inhibitor. This recommendation is based on the Hokusai-VTE study which did not suggest a difference in efficacy between reduced-dose and standard-dose edoxaban for VTE treatment. 39 The European
Summary of Product Characteristics recommends a dose reduction of edoxaban by 50% for NVAF and VTE in patients who concomitantly receive cyclosporine. 
| MANAGEMENT OF DOACS AT TIME OF TRANSPLANTATION SURGERY
An important consideration with the use of DOACs for anticoagulation in solid organ transplantation candidates is the need for reversal prior to transplantation or any urgent surgery. Recommendations for warfarin suggest stopping it for 5 days before a planned operation or utilizing a reversal agent to facilitate urgent surgical procedures. 69 Historically, fresh-frozen plasma (FFP) and low-dose 3-factor prothrombin complex concentrates (3F-PCCs) have been utilized for warfarin reversal prior to heart transplantation. 70 More recently, with the approval of Kcentra ® , 4-factor PCCs have been utilized for warfarin reversal prior to heart transplantation, providing a reduction in total volume of blood products needed, without reported thromboembolic complications. 71 Similar strategies have been utilized for other types of solid organ transplantation. The introduction of the DOACs makes utilization of these recommendations difficult and ineffective, as discussed below.
The half-lives of DOACs vary considerably based on age, renal and hepatic function, and drug interactions. 3, 72 Recommendations for discontinuation of each specific agent are based on the medication halflife which is valuable in patients who have a scheduled date of surgery (Table 3) . Unfortunately, there are no current studies that describe the function, and drug interactions play a role in determining the half-life of these agents, surgery may need to be delayed for as long as 5 days, based on discontinuation of the agent alone. 73, 74 Dabigatran is the only DOAC that can be removed by hemodialysis. In the setting of kidney transplantation, this is potentially useful for patients who present for transplant with available access to undergo hemodialysis prior to transplantation. Of note, hemodialysis removes approximately 60% of the plasma concentration of dabigatran in 2-3 hours. 4, 12 Clinicians should be aware that due to the lipophilicity of dabigatran, it concentrates very well within tissue; a drug rebound effect has been observed in which a redistribution of dabigatran from the extravascular to the intravascular space occurs within a few hours after hemodialysis. outcomes is currently unknown. 83 The use of idarucizumab in place of hemodialysis is intriguing in organ transplant candidates prior to surgery. Additional information about recurrent use of idarucizumab will be critical before its use prior to transplantation, as well as information about its repeat use, due to the potential for the formation of antibodies targeted against idarucizumab.
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Reversal agents for Xa inhibitors are not currently available. In general, the use of activated clotting factors such as factor eight inhibitor bypassing activity (FEIBA), recombinant activated factor seven (rFVIIa), and inactivated 4F-PCCs have been largely ineffective for reversal of DOACs in healthy volunteers. 3, 84, 85 While reports of successful reversal of dabigatran with FEIBA exist, caution should be employed when using this agent for reversal due to a potential increased risk of thrombosis. 86 The primary indication for the use of DOACs and the thrombogenic nature of the transplant surgery should be taken into consideration prior to utilizing these reversal modalities. Additionally, it is important to note that fresh-frozen plasma (FFP) is not effective for reversing the DOACs.
There is currently one reported case describing the use of DOAC prior to bilateral lung transplantation, without reversal beforehand.
The authors utilized rotational thromboelastography (ROTEM ® ) traces before, during, and after surgery, in addition to standard assays of hemostasis, to transplant a patient who took 20 mg of rivaroxaban 30 hours prior to surgery. No blood products, coagulation factors, or reversal agents were administered, and no bleeding events were reported. 87 This case highlights the potential for no reversal at the time of transplant surgery, albeit under controlled conditions. The reinitiation of DOACs postsurgery should be started when hemostasis has been effectively achieved, with approval of the transplant surgeon.
| SYSTEMIC ANTICOAGULATION IN IMMEDIATE POST-TRANSPLANT PERIOD
Ischemia-induced injury to the kidney both during the procurement period and transplant surgery can lead to temporarily reduced graft function in the immediate post-transplant period, with (DGF) or without (slow graft function) the requirement for hemodialysis in 25% of deceased-donor recipients and 3%-5% of living-donor recipients. 88, 89 Recipients of nonrenal solid organ transplants are also at risk for acute kidney injury (AKI) resulting from cardiac or hepatic failure, prolonged surgery, and nephrotoxic effects of immunosuppression with incidence of AKI being 25%, with 8% of patients requiring renal replacement therapy. 90 Therefore, use of DOACs in the immediate post-transplant period can be challenging. Also, most episodes of acute rejection of kidney allografts occur within the first 6 months after transplantation, with many such episodes occurring early after surgery, necessitating a higher dose of CNIs and an emergent biopsy.
Given the unpredictable renal function and drug-drug interaction and the potential need for an immediate reversal of anticoagulation prior to biopsy, it may be reasonable to avoid the use of DOACs in the immediate post-transplant period until a stable renal allograft function has been achieved, especially in deceased-donor kidney transplants and in high-immunological risk kidney transplants.
| CONCLUSION
DOACs are an alternative option to warfarin for anticoagulation in the general population for selected indications. These agents do not require monitoring and are potentially safer than and at least as efficacious as warfarin. Despite these benefits, there are specific limitations that should also be taken into consideration before using DOACs in 
